Biogen (BIIB) PT Lowered to $210 at Truist Securities; 'Focus on Topline Growth/Pipeline'
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas lowered the price target on Biogen (NASDAQ: BIIB) to $210.00 (from $220.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
